Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Internal Medicine | Critical Care | Emergency Medicine | Pediatrics | Pharmacy | Pulmonology | Journal

Back to Journal Articles

Intravenous Salbutamol Ups Mortality in Early ARDS

Last Updated: December 12, 2011.

 

Recruitment for acute respiratory distress syndrome study stopped due to safety concerns

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with acute respiratory distress syndrome, treatment with intravenous salbutamol in the early course of disease is associated with a significant increase in 28-day mortality, according to a study published online Dec. 12 in The Lancet.

MONDAY, Dec. 12 (HealthDay News) -- For patients with acute respiratory distress syndrome (ARDS), treatment with intravenous salbutamol in the early course of disease is associated with a significant increase in 28-day mortality, according to a study published online Dec. 12 in The Lancet.

Fang Gao Smith, M.D., from the University of Warwick in the United Kingdom, and colleagues investigated whether treatment with salbutamol in the early course of ARDS improved clinical outcomes. Between December 2006 and March 2010, 326 patients (aged 16 years or older) who were intubated and mechanically ventilated within 72 hours of ARDS onset were randomly assigned to receive 15 µg/kg ideal body weight/hour of salbutamol (162 patients) or placebo (164 patients) for up to seven days. Death within 28 days of randomization was the primary outcome; analysis was by intention-to-treat.

The investigators found that one patient in each group withdrew consent. Salbutamol treatment increased 28-day mortality compared with placebo treatment (34 and 23 percent of patients, respectively; risk ratio, 1.47). After the second interim analysis, recruitment was stopped due to safety concerns.

"Treatment with intravenous salbutamol early in the course of ARDS was poorly tolerated. Treatment is unlikely to be beneficial and could worsen outcome," the authors write.

Several authors disclosed financial ties to GlaxoSmithKline and AstraZeneca, both of which manufacture salbutamol.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: ASH: Chemo Alone Improves Long-Term Hodgkin's Survival Next: Dysfunctional Dynamics Seen in Pain Pathways in Migraine

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.